Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Active surveillance (AS) is chosen by 31% of favorable intermediate-risk prostate cancer patients. The 17-gene Genomic Prostate Score (GPS) and percent positive cores significantly influence AS selection in these patients.
Area Of Science
- Urology
- Oncology
- Genomics
Background
- Active surveillance (AS) is a management strategy for low-risk prostate cancer (PCa).
- Favorable intermediate-risk (FIR) PCa patients may be candidates for AS.
- The 17-gene Genomic Prostate Score (GPS) assay provides risk stratification for PCa.
Purpose Of The Study
- To identify factors associated with AS use in NCCN FIR PCa patients.
- To evaluate the impact of the GPS assay on AS decision-making.
- To analyze the relationship between GPS results and AS selection.
Main Methods
- Retrospective analysis of 324 FIR PCa patients who received a GPS assay.
- Logistic regression models (uni- and multivariable) to assess AS selection predictors.
- Calculation of AS selection proportions and confidence intervals.
Main Results
- 31% of patients selected AS, with higher GPS scores correlating with lower AS use.
- GPS results (0-19: 58%, 20-40: 27%, 41-100: 6%) and percent positive cores were significant predictors of AS selection.
- Multivariable analysis confirmed GPS and percent positive cores as significant factors.
Conclusions
- GPS assay results and percent positive cores are associated with AS use in FIR PCa.
- These factors aid in clinical decision-making for AS in intermediate-risk PCa.
- High AS persistence (91% at 12 months) suggests patient and physician confidence in AS selection.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.